魏嘉

1)Shi T, Liu W, Luo Y, Liang K, Ren S, Song X, Liu F, Lu C, Hirschhorn D, Wang H, Zhang Y, Cai Y, Wang Y, Pan Y, Liu W, Nie Y, Zhang Z, Yu L, Ding S, Liu B, Merghoub T, Li Y, Wei J. CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. Cancer Cell. 2025 Jul 29:S1535-6108(25)00313-7. doi: 10.1016/j.ccell.2025.07.007. (IF：44.5，1区) (最后通讯)

2)Liu W, Shi T, Lu C, Che K, Zhang Z, Luo Y, Hirschhorn D, Wang H, Liu S, Wang Y, Liu S, Sun H, Lu J, Liu Y, Shi D, Ding S, Xu H, Lu L, Xu J, Xin J, Liang Y, Merghoub T, Wei J, Li Y. Human myelocyte and metamyelocyte-stage neutrophils suppress tumor immunity and promote cancer progression. Cell Res. 2025 Aug;35(8):588-606. doi: 10.1038/s41422-025-01145-0. Epub 2025 Jul 15. (IF：25.9，1区) (共同通讯)

3)Shi T, Wei J. Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy. J Clin Oncol. 2025 Jan 20;43(3):350-353.(IF：42.1，1区) (最后通讯)

4)Wei J, Lu X, Liu Q, Fu Y, Liu S, Zhao Y, Zhou J, Chen H, Wang M, Li L, Yang J, Liu F, Zheng L, Yin H, Yang Y, Zhou C, Zeng P, Zhou X, Ding N, Chen S, Zhao X, Yan J, Fan X, Guan W, Liu B. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial. Nat Commun. 2023 Aug 14;14(1):4904.(IF:14.7，1区) (第一作者)

5)Liu Q, Chu Y, Shao J, Qian H, Yang J, Sha H, Cen L, Tian M, Xu Q, Chen F, Yang Y, Wang W, Wang K, Yu L, Wei J, Liu B. Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer. Adv Sci (Weinh). 2022 Nov 9;10(1):e2203298. (IF:15.1，1区)（共同通讯）

6)Chen H*, Shi T*, Wang Y, Liu Z, Liu F, Zhang H, Wang X, Miao Z, Liu B, Wan M#, Mao C, Wei J#. Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy. J Am Chem Soc. 2021 Aug 11;143(31):12025-12037. (IF：15.419，1区) (共同通讯)

7)Pan Y, Xue Q, Yang Y, Shi T, Wang H, Song X, Luo Y, Liu W, Ren S, Cai Y, Nie Y, Song Z, Liu B, Li JP, Wei J. Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. Cell Rep Med. 2024 Jun 18;5(6):101590.(IF:11.7，1区)(共同通讯)

8)Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X, Liang K, Luo Y, Che K, Wang X, Pan Y, Liu F, Yang J, Liu Q, Yu L, Liu B, Wei J. DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. Cancer Immunol Res. 2022 Dec 2;10(12):1506-1524. (IF：12.02，1区) (通讯作者)

9)Che K, Luo Y, Song X, Yang Z, Wang H, Shi T, Wang Y, Wang X, Wu H, Yu L, Liu B, Wei J. Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer. EMBO Mol Med. 2024 Feb;16(2):251-266.(IF: 9.0，1区) (通讯作者)

10)Wang Y, Wang H, Shi T, Song X, Zhang X, Zhang Y, Wang X, Che K, Luo Y, Yu L, Liu B, Wei J. Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer. EMBO Mol Med. 2024 Sep;16(9):2170-2187.(IF: 9.0，1区) (通讯作者)

11)Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y, Liu Q, Wang Q, Sun Z, Zhou S, Du S, Wei J, Liu B. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest. 2019 Mar 5;129(5):2056-2070. doi: 10.1172/JCI99538. (IF：19.456，1区) (共同通讯)

12)Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, Chen F, Du S, Zhou S, Chen H, Zhang L, Yang J, Wei J, Liu B. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun. 2019 Mar 22;10(1):1336. (IF:17.694，1区) (共同通讯)